Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alligator Bioscience ABFRA:7AL0 Cash Ratio is 1.09 as of Mar. 2026, which is 75% below its 10-year median of 4.44. The stock has 6 warning signs investors should review. Among 1,355 Biotechnology companies, Alligator Bioscience AB ranks worse than 70.92% on this metric.
Alligator Bioscience AB has a Cash Ratio of 1.09. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Alligator Bioscience AB's Cash Ratio or its related term are showing as below:
FRA:7AL0'
s Cash Ratio Range Over the Past 10 Years
Min: 0.21 Med: 4.44 Max: 43.96
Current: 1.09
During the past 12 years, Alligator Bioscience AB's highest Cash Ratio was 43.96. The lowest was 0.21. And the median was 4.44.
FRA:7AL0's Cash Ratio is ranked worse than 70.92% of 1355
companies
in the Biotechnology industry
Industry Median: 2.96
vs FRA:7AL0: 1.09
Alligator Bioscience AB (FRA:7AL0) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Alligator Bioscience AB Cash Ratio Related Terms
Alligator Bioscience AB Cash Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:7AL0 vs VRTX, REGN, RVMD: Cash Ratio Comparison
For the Biotechnology subindustry, Alligator Bioscience AB's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alligator Bioscience AB Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alligator Bioscience AB's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Alligator Bioscience AB's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alligator Bioscience AB (FRA:7AL0) has a Cash Ratio of 1.09 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Alligator Bioscience AB and its competitors. This is 75% below median its historical median of 4.44. Over the past decade, Alligator Bioscience AB's Cash Ratio has ranged from 0.21 to 43.96. According to the industry distribution chart, Alligator Bioscience AB ranks #961 out of 1355 companies in the Biotechnology industry, placing it in the top 70.9%.
Is Alligator Bioscience AB's Cash Ratio too high?
Alligator Bioscience AB's current Cash Ratio of 1.09 is 75% below median its 10-year median of 4.44. Over the past 10 years, this metric has ranged from a low of 0.21 to a high of 43.96. The Biotechnology industry median Cash Ratio is 2.96. Alligator Bioscience AB's value of 1.09 is 63.2% below this industry median. Based on the distribution chart, Alligator Bioscience AB ranks #961 out of 1355 companies in the Biotechnology industry, which is below the industry midpoint.
How does Alligator Bioscience AB's Cash Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Alligator Bioscience AB ranks #961 out of 1355 companies for Cash Ratio. This places Alligator Bioscience AB in the lower half of its industry. The industry median Cash Ratio is 2.96. Alligator Bioscience AB's value of 1.09 is 63.2% below this benchmark. Historically, Alligator Bioscience AB's own Cash Ratio has ranged from 0.21 to 43.96 over the past decade. While the company's 10-year median is 4.44 vs. the industry median of 2.96, Alligator Bioscience AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.96, based on 1,355 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alligator Bioscience AB's current Cash Ratio of 1.09 is 63.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Alligator Bioscience AB and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alligator Bioscience AB's current Cash Ratio is 1.09, which is 75% below median its own 10-year median of 4.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alligator Bioscience AB stock overvalued right now?
Alligator Bioscience AB (FRA:7AL0) has a current Cash Ratio of 1.09. The current Cash Ratio is 1.09, which is 75% below median its 10-year median of 4.44 and 63.2% below the Biotechnology industry median of 2.96. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Alligator Bioscience AB (FRA:7AL0), the current Cash Ratio is 1.09 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. The company's main drug candidate, mitazalimab, is currently under development as a therapy for metastatic pancreatic cancer patients. Its development pipeline also comprises: ATOR-4066, a bispecific antibody targeting CD40, as well as CEACAM5 (carcinoembryonic antigen 5), a protein found in certain tumors; and certain externally developed programs like HLX22 and ALG.APV-527. Geographically, the company generates maximum revenue from Belgium (mainly through out-licensing), and also has its presence in Sweden and Finland.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7AL0 has been successfully added to your 
